Jaguar Health targets mid-2027 MVID NDA filing with possible end-2027 U.S. approval, backed by up to 48% parenteral support reductions
This is a summary aggregated from Seeking Alpha. Read the complete article on the original site:
Read full article at Seeking Alpha
